SCNI
Income statement / Annual
Last year (2023), Scinai Immunotherapeutics Ltd.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Scinai Immunotherapeutics Ltd.'s net income was -$6.51 M.
See Scinai Immunotherapeutics Ltd.’s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Gross Profit |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Research and Development
Expenses |
$5.22 M
|
$5.77 M
|
$3.32 M
|
$51.42 M
|
$250.14 M
|
$66.53 M
|
$66.16 M
|
$29.92 M
|
$30.80 M
|
$20.12 M
|
General & Administrative
Expenses |
$0.00
|
$0.00
|
$7.71 M
|
$51.84 M
|
$34.09 M
|
$17.73 M
|
$16.73 M
|
$15.58 M
|
$12.71 M
|
$0.00
|
Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
-$35.17 M
|
$0.00
|
-$12.96 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General &
Administrative Expenses |
$4.51 M
|
$5.30 M
|
$7.71 M
|
$16.67 M
|
$34.09 M
|
$4.77 M
|
$16.73 M
|
$15.58 M
|
$12.71 M
|
$9.71 M
|
Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$6.83 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Operating Expenses |
$6.63 M |
$11.06 M |
$11.19 M |
-$7.33 M |
$285.51 M |
$71.30 M |
$83.36 M |
$45.69 M |
$44.03 M |
$29.83 M |
Cost And Expenses |
$6.63 M |
$11.06 M |
$11.19 M |
-$7.33 M |
$285.51 M |
$71.30 M |
$83.36 M |
$45.69 M |
$44.03 M |
$29.83 M |
Interest Income |
$123,138.00 |
$5.27 M |
$964.10 |
$3.84 M |
$14,575.71 |
$2.72 M |
$63,425.42 |
$211,153.36 |
$42,850.78 |
$0.00 |
Interest Expense |
$0.00 |
$0.00 |
$3.48 M |
$15.62 M |
$54.36 M |
$12.58 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Depreciation &
Amortization |
$514,579.00
|
$562,000.00
|
$776,103.72
|
$7.83 M
|
$5.99 M
|
$905,972.23
|
$1.55 M
|
$2.38 M
|
$2.45 M
|
$2.48 M
|
EBITDA |
-$9.20 M
|
-$10.50 M
|
-$10.43 M
|
$11.17 M
|
-$280.07 M
|
-$68.59 M
|
-$43.35 M
|
-$43.30 M
|
-$41.58 M
|
-$27.35 M
|
EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Total Other
Income/Expenses Net |
$3.21 M
|
$5.27 M
|
$1.84 M
|
-$34.14 M
|
-$57.48 M
|
$9.88 M
|
-$38.45 M
|
$10.22 M
|
$4.26 M
|
$1.38 M
|
Income Before Tax |
-$6.51 M |
-$5.80 M |
-$12.85 M |
-$4.45 M |
-$397.90 M |
-$81.17 M |
-$121.75 M |
-$35.26 M |
-$39.73 M |
-$28.45 M |
Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Income Tax Expense |
$0.28 |
$333,515.00 |
$3.48 M |
-$26.35 M |
$54.36 M |
$21.56 M |
$38.39 M |
-$211,153.36 |
-$42,850.77 |
$0.00 |
Net Income |
-$6.51 M |
-$5.80 M |
-$12.85 M |
-$4.45 M |
-$397.90 M |
-$81.17 M |
-$121.75 M |
-$35.26 M |
-$39.73 M |
-$28.45 M |
Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
EPS |
-16.69 |
-40.25 |
-125.96 |
-40.48 |
-4912.27 |
-1248.71 |
-2434.9 |
-1068.44 |
-1528.1 |
-2188.2 |
EPS Diluted |
-16.66 |
-30.74 |
-91.02 |
-40.16 |
-4872.41 |
-1241.91 |
-2422.39 |
-1043.98 |
-1506.01 |
-2095.98 |
Weighted Average Shares
Out |
$390,000.00
|
$144,000.00
|
$102,000.00
|
$110,000.00
|
$81,000.00
|
$65,000.00
|
$50,000.00
|
$33,000.00
|
$26,000.00
|
$13,000.00
|
Weighted Average Shares
Out Diluted |
$390,657.00
|
$188,519.00
|
$141,144.00
|
$110,815.00
|
$81,663.00
|
$65,355.00
|
$50,258.00
|
$33,774.00
|
$26,381.00
|
$13,572.00
|
Link |
|
|
|
|
|
|
|
|
|
|